Daito's Facts and Figures
- Top
- Company Profile
- Company Profile
- Daito's Facts and Figures
Net Sales (Consolidated)
50.6 billion yen
(Consolidated sales for the fiscal year ending May 2025)
Daito Group's sales revenue was 50.6 billion yen.
Since listing in 2010, the company has achieved substantial revenue growth for 14 consecutive periods (*), and its sales have more than doubled since its initial listing.
- The "Accounting Standard for Revenue Recognition" (ASBJ Statement No. 29) will be adopted from the fiscal year ended May 31, 2022. A comparison with estimates based on the application of the standard for the prior years before the standard's adoption will be used to determine the amount of revenue recognized.
Percentages of Sales from the Active Pharmaceutical Ingredients (API) Business and the Formulation Product Business
API business : 45 %
Pharmaceutical product business : 54 %
By handling both the active pharmaceutical ingredient (API) and the formulation, Daito can share sales information between the two departments and achieve high quality and low cost by manufacturing everything from APIs to formulation in-house. The synergistic effects between these two areas are one of Daito's strengths.
Annual Number of Tablets Daito Produces
Approx.
3,000
hundred million (3.2 billion)
(Actual figures for the fiscal year ending May 2025)
Daito produces approximately 3 billion tablets annually.
This amounts to approximately 24 tablets per person per year in Japan.
If you use medication, you've probably taken Daito's medicines at least once.
(In addition to tablets, we also manufacture granules and other formulations.)
Reduction in Japan’s National Medical Expenditure, Achieved through Daito’s Provision of Generic Drugs
425
hundred million yen (46.8 billion yen)
(Based on shipment volume for the fiscal year ending May 2025)
The generic drugs that Daito focuses on are launched after the patents of the original drugs expire, so development costs are low and their drug prices are less than 40% to 50% of the original drugs.
The cost savings from replacing the original drug with Daito's generic version amounted to approximately 42.5 billion yen.
Number of Master Files (MFs) Registered
106
(As of May 2025. Includes registrations of subsidiaries and group companies.)
The number of officially registered MFs of the company almost equals the number of API products the company manufactures. A total of 106 MFs are officially registered for Daito Group products, the largest number in Japan.
An MF is a kind of component part of an application for approval for a drug. The Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices provides that the MF for an API shall indicate its manufacturing method, specifications, etc.
If an API manufacturer intends to sell an API to another company, the manufacturer will usually register an MF for the API.
Therefore, the number of officially registered MFs of a company is an indicator of the number of API products the company manufactures.
Year of Founding
1942
Daitoa Pharmaceutical Trade Control Company,* the predecessor of Daito, was founded as a control company in charge of the export of Toyama-made home medicines to Southeast Asia.
Daito will celebrate the 80th anniversary of its founding in June 2022.
- In 1991, the Company adopted its current name: Daito Pharmaceutical Co., Ltd.
Number of Employees (Consolidated)
1,073
(Consolidated figures, as of May 31, 2025, including temporary employees)
In the Daito Group, diverse talents demonstrate their capabilities fully, irrespective of their gender, nationality or age.
The Company has continued to grow since its listing on the Tokyo Stock Exchange, and it has employed many mid-career people.
Number of Staff Members of the Quality and Regulatory Affairs Division
220
(As of June 1, 2025, non-consolidated, including temporary employees)
Daito is committed to improving the quality of pharmaceuticals, and has 220 employees in its reliability assurance department, which includes the quality assurance department and quality control department.
This represents approximately 22% of Daito's total employee numbers (consolidated).
Number of Detailers
0
Since Daito concentrates its management resources on the manufacture of APIs and Pharmaceutical products, it outsources marketing activities targeting pharmacies and medical institutions to other companies.
Therefore, the Company has no detailers (MRs), who would be in charge of pharmaceutical detailing and sale to medical institutions.